The Hazy Economics of Breathing: Can Supplements Beat Wildfire Smoke?

NEW YORK, NY – June 15, 2026 – As an ominous haze blankets vast swaths of the United States, the 2026 wildfire season is already living up to its dire predictions. With over 2.5 million acres burned by mid-June—nearly double the 10-year average—millions of Americans are confronting a new seasonal reality defined by air quality alerts and the acrid smell of distant forests burning. This is not merely smoke; it's a toxic brew of fine particulate matter (PM2.5), carbon monoxide, and chemicals that, according to the EPA, can penetrate deep into the lungs, triggering everything from short-term illness to the exacerbation of chronic heart and lung diseases.

Into this public health crisis steps a rapidly growing segment of the wellness industry. Companies are now marketing dietary supplements as a form of proactive defense against the invisible threat in the air. A prominent example is Betterbrand, which is promoting its BetterLungs supplement as a “daily defense against the damaging effects of wildfire smoke.” This trend marks a significant new frontier for the $150 billion global supplement market, raising critical questions for consumers and investors alike: Is this a valid, science-backed approach to respiratory resilience, or is it simply a well-marketed placebo for an anxious populace? As executive investors, we must look beyond the press releases to analyze the science, the market dynamics, and the underlying risks.

A Market Forged in Smoke

The demand for respiratory solutions is not speculative; it's a visceral response to a tangible threat. Research confirms the danger is escalating. A recent Stanford study concluded that the particulate matter from wildfire smoke is up to 10 times more toxic than pollution from burning fossil fuels. This reality has created a fertile ground for a new category of consumer health products focused on what can be called 'proactive lung health.'

Companies like Betterbrand are capitalizing on this burgeoning market. Founded in 2019 by a Doctor of Pharmacy, the company has built a direct-to-consumer brand that speaks directly to health-conscious individuals seeking control in an uncontrollable environment. Its marketing highlights a formula of “science-backed” natural ingredients designed to help the body clear toxins and reduce inflammation—precisely the kind of support a person might seek when the air outside is deemed 'Unhealthy' or 'Hazardous.'

This strategy is emblematic of a broader trend in the wellness space. Where consumers once bought supplements for athletic performance or general vitality, they are now buying them to mitigate environmental threats. This shift represents a significant market opportunity. The drivers are powerful and persistent: worsening climate impacts, a heightened sense of personal health responsibility post-pandemic, and a consumer base conditioned to seek solutions online. For a company like Betterbrand, which claims to have served over one million customers, the strategy is clearly resonating. The investment thesis is simple: as long as the skies fill with smoke, the demand for products that promise a clearer breath will likely grow.

Scrutinizing the Science-Backed Claims

For an investor, market demand is only half of the equation. The other half is product viability, which hinges on efficacy and regulatory standing. Here, the landscape becomes significantly more complex. The term “science-backed” is a powerful marketing tool, but in the world of dietary supplements, it operates in a gray area.

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the FDA regulates supplements as food, not drugs. This means companies can't claim their products diagnose, treat, cure, or prevent any disease. They are, however, responsible for substantiating their “structure/function” claims, such as “supports lung health.” The rigor of that substantiation is not held to the same standard as pharmaceutical drugs, leaving significant room for interpretation.

An examination of the key ingredients in a product like BetterLungs reveals this nuance. N-acetyl cysteine (NAC), for instance, is a well-studied compound used in clinical settings to thin mucus and as an antidote for acetaminophen overdose. It also boosts the body’s production of glutathione, a primary antioxidant. Theoretically, this could help combat the oxidative stress caused by smoke particles. However, there are no large-scale clinical trials demonstrating that taking an NAC supplement prevents or mitigates the specific damage from inhaling wildfire smoke. The evidence for other ingredients, like mullein leaf, elderberry, and reishi mushroom, is even less direct. While they have traditional uses for soothing respiratory irritation or supporting immune function, robust, peer-reviewed studies linking them to protection against PM2.5 and airborne toxins are scarce.

Independent medical experts urge caution. “While some of these ingredients have known antioxidant or anti-inflammatory properties, their ability to counteract the complex and severe assault of wildfire smoke on the respiratory system has not been established in clinical studies,” stated a professor of pulmonology at a major university medical center. “We worry about a false sense of security. Relying on a supplement could lead people to neglect proven protective measures, which could have serious health consequences.”

The Investor's Guide to Respiratory Resilience

From an investment perspective, the proactive lung health market presents a compelling but high-risk opportunity. The growth narrative is undeniable. However, savvy investors must weigh this against significant regulatory, reputational, and efficacy risks. A crackdown by the FDA or FTC on companies whose claims are deemed misleading could have a devastating impact on brand value. More importantly, the long-term viability of this market segment depends on perceived consumer benefit. While anecdotal testimonials can drive initial sales, a product category that fails to deliver a tangible, consistent effect may struggle with customer retention.

Therefore, a more durable investment strategy may lie in the markets for evidence-based solutions. The most effective defenses against wildfire smoke are well-established, and the companies providing them are positioned for sustained growth without the same level of claim-substantiation risk. This includes:

• Air Filtration Technology: The market for high-efficiency particulate air (HEPA) purifiers and high-grade HVAC filters (MERV 13 and above) is booming. These products offer a mechanically proven method of removing harmful particulates from indoor air, a recommendation universally endorsed by public health agencies.

• Personal Protective Equipment (PPE): Manufacturers of NIOSH-certified N95 and P100 respirators represent another critical investment area. Unlike supplements, the efficacy of these devices in filtering airborne particles is rigorously tested and certified.

• Pharmaceuticals and Medical Care: Companies developing and supplying treatments for asthma, COPD, and other respiratory conditions will continue to see demand as smoke events exacerbate these illnesses.

Public health officials are unequivocal in their guidance. As one state health department official noted, “Our recommendations are based on decades of scientific evidence: stay indoors, create a clean-air room with a HEPA filter, and wear a properly fitted N95 respirator if you must go outside.” For the executive investor, the challenge lies in discerning between the companies selling evidence-based protection and those simply selling a compelling story in the smoke-filled air.